Navigation Links
ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
Date:9/19/2012

BARCELONA, Spain, September 19, 2012 /PRNewswire/ --

ESTEVE's R & D team includes a total of 350 people, 13% of the total global workforce, with the capability to work in all areas of drug discovery and the development of new medicines. This new R&D Center will house 92 scientists focused on two key phases in drug development; (1) The discovery phase, the phase during which new chemical entities are identified that may have the ability to positively change the course of a disease and, (2) the preclinical development phase, which includes performing all the necessary tests to provide the appropriate evidence to allow a new drug to be evaluated in humans.

The transfer to the PCB is an example of ESTEVE's commitment to research, despite the difficult socio-economic environment, as a way to maintain long-term sustainability. One of the keys to this sustainability is the ability to provide innovative solutions to medical needs that have not yet been adequately met. In this new facility, the company expects to increase performance in its R & D activities, improving the overall productivity of the discovery process in the development of new drugs and shorten the time to market.

This is the first alliance of its kind, where a large pharmaceutical company will locate all key competence units for drug discovery and preclinical development in a top quality academic / scientific environment in Spain.

The decision-making process to transfer the R & D team to the PCB took into consideration several factors, the most notable of which is the excellent infrastructure, the advantages of working in a high quality scientific and technical environment and the presence, in a common area, of scholars, researchers, talented young people and groups of entrepreneurs. It represents a further step towards a single model of open innovation in pharmaceutical R & D. ESTEVE's key strategy in R & D is an active policy of creating strategic alliances with universities, public research centres, technology companies and other companies in the sector, both in Spain and abroad

For more information go to http://www.esteve.com/investigacion-desarrollo


'/>"/>
SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
Breaking Medicine News(10 mins):